Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashley Eheim

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Seminars in Immunopathology|November 12, 2013
Immune cells and metabolic dysfunctionAshley Eheim, Dasa Medrikova, Stephan Herzig
Molecular Cancer Therapeutics|August 18, 2018
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of ResistanceMaria Quanz, Eckhard Bender, Charlotte Kopitz, et al.
Leukemia|April 4, 2019
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesSven Christian, Claudia Merz, Laura Evans, et al.
Iscience|September 14, 2020
Identification of Small Molecules that Modulate Mutant p53 CondensationClara Lemos, Luise Schulze, Joerg Weiske, et al.
ACS Chemical Biology|July 6, 2017
Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer TargetManuel Ellermann, Ashley Eheim, Fredrik Rahm, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Seminars in Immunopathology|November 12, 2013
Immune cells and metabolic dysfunctionAshley Eheim, Dasa Medrikova, Stephan Herzig
Molecular Cancer Therapeutics|August 18, 2018
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of ResistanceMaria Quanz, Eckhard Bender, Charlotte Kopitz, et al.
Leukemia|April 4, 2019
The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignanciesSven Christian, Claudia Merz, Laura Evans, et al.
Iscience|September 14, 2020
Identification of Small Molecules that Modulate Mutant p53 CondensationClara Lemos, Luise Schulze, Joerg Weiske, et al.
ACS Chemical Biology|July 6, 2017
Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer TargetManuel Ellermann, Ashley Eheim, Fredrik Rahm, et al.
Pageof 1